Compare Amgen, Inc. (AMGN) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | SGOV | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Fixed Income |
52-Week High | $388.16 | $100.74 |
52-Week Low | $271.18 | $100.28 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.50, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend from moving averages, though oscillators are neutral. The ETF functions as a cash management vehicle, holding ultra-short-term U.S. Treasury bills, with key financial ratios like P/E and P/B not applicable due to its structure. Recent news highlights strong investor inflows into short-term bond ETFs amid rate uncertainty.
The outlook for SGOV remains stable, offering a low-risk haven for cash with yields around 3.5–3.6%, appealing in volatile markets. Risks include potential Fed rate hikes reducing relative yield appeal and inflation eroding returns. Analyst sentiment is positive for its role in agile, income-focused portfolios, but investors should weigh opportunity costs against equity investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
